跳转至内容
Merck
CN

20350

ORBO Supelpak 20 系列管

greener alternative

RC,GFF,F,F (specially cleaned) separators, O.D. × L 13-8 mm × 75 mm , OSHA Versatile Sampler (OVS) Tube, pkg of 10 ea

别名:

ORBO Supelpak 20 series Tube

登录 查看组织和合同定价。

选择尺寸


关于此项目

UNSPSC Code:
47131900
NACRES:
NB.21
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

产品名称

ORBO Supelpak 20 系列管, RC,GFF,F,F (specially cleaned) separators, O.D. × L 13-8 mm × 75 mm , OSHA Versatile Sampler (OVS) Tube, pkg of 10 ea

Quality Level

material

RC,GFF,F,F (specially cleaned) separators

agency

NIOSH 5601
OSHA 62,63,67,70,74

product line

Amberlite
ORBO

composition

Bed A, 270 mg
Bed B, 140 mg

packaging

pkg of 10 ea

manufacturer/tradename

ORBO 49P

sustainability

Greener Alternative Product

technique(s)

active air sampling: suitable

O.D. × L

13-8 mm × 75 mm , OSHA Versatile Sampler (OVS) Tube

matrix

XAD-2 (specially cleaned)

particle size

20-40 mesh

application(s)

air monitoring
environmental
industrial hygiene

greener alternative category

正在寻找类似产品? 访问 产品对比指南

General description

The OSHA Versatile Sampler (OVS) was primarily designed for collection of Organophosphorus pesticides but is suitable for other applications. This specially constructed open glass tube is 75 mm long with a 13-mm outer diameter (O.D.) on the inlet end tapered to 8 mm (O.D.) on the outlet end. The design features a glass filter to trap the aerosols and a two-section sorbent portion to adsorb the vapors. The tube is packed with specially cleaned XAD-2 material and is QA tested to ensure low background interferences. The product is capped at the inlet and outlet to minimize environmental exposure. Meets OSHA and NIOSH method design specifications.
We are committed to bringing you Greener Alternative Products. This product is a Design for Sustainability (DfS) developed product, which belongs to one of the four categories of greener alternatives. Click here to view its DfS scorecard.

Legal Information

Amberlite is a trademark of DuPont de Nemours, Inc.
ORBO is a trademark of Sigma-Aldrich Co. LLC
Supelpak is a trademark of Sigma-Aldrich Co. LLC
XAD is a registered trademark of The Dow Chemical Company or an affiliated company of Dow

存储类别

10 - Combustible liquids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

法规信息

新产品
此项目有

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our 文件 section.

如需帮助,请联系 客户支持

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

F J Egea González et al.
Journal of AOAC International, 80(5), 1091-1097 (1997-11-05)
A method to sample and analyze chlorothalonil and dichlofluanid in greenhouse air was evaluated. Analysis was performed by gas chromatography with electron capture detection and gas chromatography-mass spectrometry. Solid sorbents such as Chromosorb 102, Porapak R, Supelpak-2, Amberlite XAD-2, Amberlite
Anne Beate Vereide et al.
Gynecologic oncology, 97(3), 740-750 (2005-05-12)
The aim of the study was to investigate apoptosis as a growth regulatory mechanism of gestagen in endometrial precancers and to compare differences in the apoptotic cascade after high and low dose gestagen regimens. Pre- and post-treatment paraffin-embedded endometrial hyperplasia
H Stalsberg et al.
Virchows Archiv. A, Pathological anatomy and histopathology, 414(5), 415-422 (1989-01-01)
The autopsies of 12 victims from two snow avalanches in North-Norway are reported. Supportive evidence from non-autopsied and surviving victims is included. Consistent autopsy findings were prominent lung oedema, moderate cerebral oedema, extreme contraction of the left ventricle, petechiae in
Anne Ørbo et al.
The Journal of steroid biochemistry and molecular biology, 113(1-2), 139-149 (2009-01-14)
Patients with endometrial hyperplasia representing preliminary stages of endometrial cancer have shown to respond to therapy in 100% of the cases when treated with levonorgestrel-impregnated intrauterine device. Anti-proliferative effect has also been reported after application of an anti-progestin impregnated intrauterine
A Ørbo et al.
BJOG : an international journal of obstetrics and gynaecology, 123(9), 1512-1519 (2015-12-03)
To investigate relapse rates after the successful treatment of patients with non-atypical endometrial hyperplasia who were randomised to either a levonorgestrel-impregnated intrauterine system (LNG-IUS; Mirena(®) ) or two regimens of oral medroxyprogesterone acetate (MPA) after primary histological response. A multicentre

相关内容

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持